Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras homolog family member T1 pseudogene 2 (RHOT1P2) is classified as a **pseudogene**, meaning it is a DNA sequence that resembles a protein-coding gene—here, the RHOT1 gene encoding the mitochondrial Rho GTPase 1—but carries mutations or features that prevent it from producing a functional protein product[1][3]. Unlike its parent gene, pseudogenes like RHOT1P2 typically do not code for proteins and are not considered receptors, enzymes, transporters, or canonical pharmaceutical targets. Recent research suggests some pseudogenes can exert regulatory effects on gene expression, usually by acting as competitive endogenous RNAs ("miRNA decoys") or influencing RNA stability, but there is no direct evidence of such a function for RHOT1P2 specifically[1][3]. There is no indication that RHOT1P2 plays a role in disease, serves as a drug target, or is used as a biomarker. **In summary:** This entry is a pseudogene, not a canonical drug target, and lacks known biological, therapeutic, or diagnostic significance[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras homolog family member T1 pseudogene 2 (RHOT1P2).